Recent advances in koala vaccination against chlamydia are providing valuable insights for human vaccine development. Koalas are the first wildlife species to receive conditional approval for a chlamydia vaccine, enabling researchers to observe real-world disease outcomes and vaccine effectiveness over time. Field studies have demonstrated reduced disease rates and mortality among vaccinated koalas, without evidence of bacterial resistance. This research highlights the potential of wildlife vaccination programs to inform human health strategies, particularly for complex pathogens, and underscores the importance of alternative models when traditional clinical trials are not feasible.

T-cell engaging therapies just took a great leap forward: a single injection of a modified self-amplifying RNA (saRNA) can mediate long-term clearance of malignant B cells, effectively bypassing the need for continuous intravenous infusions.

This new preprint originates from the collaborative research at Boston University. The study was driven by researchers Chloe (Kexin) Li and Joshua McGee, under the leadership of Dr. Wilson Wong and Dr. Mark Grinstaff.

Bispecific T cell engagers (BiTEs), such as the FDA-approved Blinatumomab, are highly effective cancer immunotherapies but are severely bottlenecked by their pharmacokinetics. With a remarkably short half-life of around 2 hours, conventional BiTEs require continuous daily intravenous infusions across multiple weeks, which drastically limits patient access and drives up healthcare costs. Further, the rapid peak of BiTEs can trigger severe adverse events like cytokine release syndrome (CRS). While utilizing mRNA to express BiTEs in vivo circumvents manufacturing hurdles, transient expression still dictates weekly dosing regimens.

To overcome this, the team engineered a 5-methylcytidine (m5C)-modified saRNA-BiTE system formulated in lipid nanoparticles (LNPs) targeting CD19. By leveraging the self-replicating nature of saRNA, the platform acts as an in situ bioreactor, achieving a durable, steady-state pharmacokinetic profile from a single systemic administration.

Key takeaways:
• saRNA-BiTE induces robust, antigen-specific lysis of CD19+ target cells (Nalm6 and Raji). saRNA-BiTE maintains target cell killing for a full week post-transfection across all tested doses, whereas the efficacy of the mRNA-BiTE counterpart rapidly declines over the same period.

• Systemically administered saRNA avoids the initial burst exposure typical of standard mRNA therapies. In murine models, saRNA-encoded proteins maintained higher serum concentrations beyond day 14 compared to mRNA

• To simulate the incomplete leukemic cell depletion often seen in human patients, the team utilized a Nalm6 acute lymphoblastic leukemia (ALL) rechallenge model with 8 successive tumor injections. A single 3 µg dose of saRNA-BiTE completely eradicated malignant cells and prevented disease recurrence for 3 months. By the end of the study, mice treated with mRNA-BiTE and Blinatumomab had all relapsed.

•Ex vivo serum killing assays confirmed that mice treated with saRNA-BiTE maintained functional BiTE expression in circulation for up to 6 to 7 weeks post-administration.

This innovative research establishes saRNA as a highly robust platform for extended in situ therapeutic protein production. By translating continuous BiTE infusions into a single, off-the-shelf LNP injection, this approach mitigates manufacturing bottlenecks associated with complex recombinant proteins.

You can read the cool preprint here: https://lnkd.in/e2M_b2Fy

#BITE #TCE #saRNA #Immunotherapy

Exciting developments for CAR-T in solid tumors "urokinase-type plasminogen activator receptor (uPAR) CAR-T cells"

Turning mosquitoes into "flying vaccines"? Science is getting creative in the fight against infectious diseases.

A fascinating new line of research explores how mosquitoes could be used to deliver vaccines to wild bats-helping stop dangerous viruses like rabies and Nipah at their source before they spill over into humans.

Here's the idea:

Mosquitoes are engineered to carry a harmless vaccine virus

When they bite bats, they "inject" immunity

Alternative approach: mineral-rich drinking stations with edible vaccines

Why this matters:

Bats are natural reservoirs for many high-risk viruses, and traditional vaccination methods simply don't work at scale in wild populations. Instead of culling (which can backfire), scientists are looking at ecological, non-invasive solutions.

Early results are promising:

Vaccinated animals developed protective antibodies

Bats were successfully immunized via bites,
ingestion, and drinking

Some survived otherwise lethal virus exposure

Of course, big questions remain-especially around environmental safety, regulation, and real-world deployment.

But this approach signals something bigger:
A shift toward stopping pandemics at the source, not just reacting to them.
Innovations like this could redefine how we manage zoonotic diseases in an increasingly interconnected world.

#GlobalHealth #Vaccines #IntegratedPestManagement
#CommercialPestControl
#FoodSafetyStandards
#EnvironmentalHealth #PublicHealthProtection #QualityAssurance
#RiskManagement #BrandProtection #ComplianceManagement #GlobalStandards
#Innovation #OneHealth #PublicHealth
#Science #PandemicPrevention

"Continued Anticomplement #Therapy: A Lifeline for Post-Renal-Transplant Patients with Complement-Mediated Hemolytic Uremic Syndrome"

🖋️ by Natasha Venugopal, Hyma V. Polimera, Jessica Santucci, Erik Washburn and Elizabeth Federici

🔗 https://brnw.ch/21x1a0V

Le Dr Isabelle Nel, PHU en Immunologie biologique à l'Hôpital Robert Debré, a récemment partagé un article sur l'utilisation des anticorps thérapeutiques.

Vous pouvez consulter cet article sur notre site via le lien suivant : https://lnkd.in/ebi4yJYV

𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐢𝐧 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dFNjk8eY

The global vaccines market (excluding COVID-19 vaccines), valued at USD 49.59 billion in 2024, stood at USD 47.65 billion in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2030, culminating in a forecasted valuation of USD 67.91 billion by the end of the period.

The market is growing due to several factors, including the rapid development and global commercialization of vaccines, the increasing prevalence of infectious diseases that require vaccination for prevention, the rising number of immunization programs, advancements in technology that support vaccine development, and increased government support through investments and funding aimed at creating new vaccines for various disease indications.

• The North America vaccines market accounted for a 52.3% revenue share in 2024.

• By disease indication, the pneumococcal disease segment is expected to register the highest CAGR of 10.6%.

• By technology, the inactivated & subunit vaccines segment is projected to grow at the fastest rate from 2025 to 2030.

• By end user, the adult vaccines segment accounted for a larger share of 54.0% of the market in 2024.

• Companies such as GSK, Merck Group, Pfizer were identified as some of the star players in the vaccines market (global), given their strong market share and product footprint.

• Companies such as SINOVAC BIOTECH LTD., Incepta Pharmaceuticals Ltd., Valneva among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders

🐄 Understanding Vaccination & Antibody Titre Dynamics in Dairy Cattle 🧬

Effective vaccination is not just about injecting vaccines—it’s about understanding how the immune system responds and how long protection lasts.

🔬 What happens after vaccination?
The animal’s immune system produces antibodies. The first response is slow and low, while booster doses create a faster and stronger immunity.

📊 Antibody Titre Dynamics:
Antibody levels follow a pattern:
➡️ Lag Phase → 📈 Peak → 📉 Decline

This is why timely booster doses are essential to maintain protection.

🐮 Maternal Antibodies in Calves:

- Obtained through colostrum
- Provide early protection
- Can interfere with early vaccination

⏳ Proper timing of vaccination in calves is critical to avoid vaccine failure.

📅 Practical Vaccination Strategy:

- Calves: 3–6 months
- Boosters: 2–4 weeks after first dose
- Adults: Annual or biannual vaccination

⚠️ Factors Affecting Immune Response:

- Nutrition (Protein, Zinc, Selenium)
- Stress & disease conditions
- Proper vaccine storage & handling (cold chain)

🧪 Why Antibody Titre Testing Matters?

- Evaluate vaccine effectiveness
- Monitor herd immunity
- Optimize vaccination programs
(Common method: ELISA)

💡 Key Takeaways:
✔ Boosters are critical
✔ Good nutrition improves immunity
✔ Monitor and adapt vaccination plans

🌱 Strong immunity = Healthy herd = Better productivity

#DairyFarming #HerdHealth #DairyNutrition

🔬 Antibody-guided vaccine design is shaping the next generation of immunization. By leveraging epitope-, nanoparticle-, and scaffold-based strategies, researchers aim to achieve more precise and durable immune protection.

Challenges remain across diverse pathogens — from influenza A and HIV to malaria, RSV, and SARS-CoV-2 — yet advances in immunogenetics and personalized vaccines may unlock stronger, more targeted antibody responses.

👉 How do you see the balance between universal and personalized vaccines evolving in the coming decade?

📖 Read the full article here:
https://lnkd.in/dGpXeSB3

#VaccineDesign #Immunology #AntibodyResearch #NextGenVaccines #InfectiousDiseases #BiomedicalResearch #GROWTHresearchgroup #SUMMITproject #velikovamd

A clinical study shows how the intranasal FluMist vaccine can elicit potent antiflu immunity at mucosal sites, researchers tie persistent T cells in the liver to clinical cure of chronic hepatitis B, and more this week in #ScienceTranslationalMedicine.

https://scim.ag/4vY4WbW

A recent publication in Nature Medicine reports 5-year follow-up data from a phase 3 trial evaluating a single-dose live attenuated tetravalent dengue vaccine (Butantan-DV). The results show an overall efficacy of about 65% against symptomatic dengue and around 80% against severe forms, with no safety signal identified over the follow-up period .

An important aspect of dengue immunology needs to be considered when looking at longterm protection. Dengue is characterized by the coexistence of four serotypes. Infection with one serotype induces protection against that specific serotype but may increase the risk of severe disease upon subsequent infection with a different serotype. This phenomenon called antibody-dependent enhancement (ADE), is explained by the impact of non-neutralizing or subneutralizing antibodies that facilitate viral entry into host cells.

A key point is that these potentially enhancing antibodies do not appear immediately after infection or vaccination. They may emerge over time as
antibody levels decline and the balance between neutralizing and non-neutralizing responses shifts. This temporal dynamic is one of the reasons
why long-term follow-up is essential in dengue vaccine studies. The vaccine is designed to induce balanced immunity against all four dengue serotypes and thereby prevent the emergence of enhancing antibodies; however, this remains a theoretical goal, as neutralizing responses are not equally induced against each serotype, which may favor the development of non-neutralizing, potentially enhancing antibodies

In this study, vaccine efficacy remained significant over five years, including in
individuals without prior dengue exposure, and no increase in severe dengue
cases was observed in vaccinated participants . These findings are particularly relevant given previous experience with dengue vaccines, where safety concerns emerged only several years after vaccination in seronegative
individuals.

Overall, these results support the importance of sustained efficacy and long-term safety assessment when evaluating dengue vaccines, in a context where immune responses can evolve over time and influence disease risk upon subsequent exposure.

#Denguevaccine #Butantan

https://lnkd.in/eMg3yrsU

A new order in cell therapy

The interim futility analysis for cema-cel, just gave the lymphoma field something to think about. A 41.6% absolute difference in MRD negativity at Day 45 versus observation, with clean tolerability, availability in community hospitals and most patients managed as outpatients. It is a meaningful signal that allogeneic CAR-T can work in first-line consolidation post R-CHOP.

What about the patients who relapse after cema-cel? Go back to CD19 with an autologous product: Yescarta, Breyanzi? They all target the same CD19 as cema-cel. Would a second CD19 CAR-T be reimbursed? If cema-cel moves towards commercialization in LBCL, patients who relapse will need a subsequent differentiated option. The commercial case for CD19-targeted autologous therapies in this setting will need rethinking.

This is where eti-cel becomes relevant. A highly differentiated product also developed at Cellectis, on the same backbone as cema-cel (originated from Cellectis platform), eti-cel targets both CD20×CD22 simultaneously. Data at the current dose show 88% ORR and 63% CR in heavily pretreated patients, a strong signal for a dual allogeneic approach.

Fifteen years ago, CAR-T emerged as a revolution. The real breakthrough, the bona fide pharmaceutical product, is allogeneic. Off-the-shelf, scalable, standardized. It will establish a new order in cell therapy. Autologous therapies are a process and will, in time, disappear.

On in vivo CAR-T: the science is early, the toxicity profile remains unfavorable today, and the regulatory path for a therapy where the vector is the product is, at best, unclear.

Cellectis Allogene Therapeutics Kite Pharma Bristol Myers Squibb Novartis Johnson & Johnson Gilead Sciences
#dlcl #CART #celltherapy #allogeneic | 14 comments on LinkedIn

VACCINES are most effective in harnessing the immune system to produce high levels of antibodies to stable and accessible targets. BUT, malaria parasites, HIV, and the influenza virus are capable of hiding their weakest parts from the immune system.

WHAT IF the immune system could be PROGRAMMED to produce high levels of those rare antibodies capable of finding and neutralizing the most vulnerable pathogenic features of these parasites? In this weeks issue of Science, Hartweger et al. (2026, Science 392, eadz8994) reported findings using a mouse model, in which they demonstrated that the self-amplification properties of the immune system could be harnessed to produce high levels of these rare neutralizing therapeutic antibodies. They used hematopoietic stem and precursor cells (HSPCs) to give rise to B lymphocytes activated to produce high titers of long-lasting neutralizing antibodies in mice that protected them from a lethal influenza infection.

Here is a news article highlighting this seminal research, and the avenues it has opened for future therapies for human diseases and infections:

https://lnkd.in/gEy-bemG

A malaria vaccine showing up to 90% protection in early clinical studies and a key question: how does it work? That’s what the European CAPTIVATE consortium is working on. BPRC is a partner.

https://lnkd.in/ekNSR4Jw

In Antwerp, researchers from across Europe came together to share progress and align next steps.

The CAPTIVATE consortium approach is fundamentally different. Instead of using fragments of the parasite, this vaccine uses a genetically attenuated version of the malaria parasite itself.

After vaccination, the parasite reaches the liver, but stops there. It cannot develop further. This allows the immune system to recognise and eliminate the parasite at the earliest stage, before it causes disease.

“The strong protection seen in healthy volunteers often doesn’t translate to endemic settings”, says Erica Pasini (BPRC). “We want to understand why and how to make it work where it matters most.”

At BPRC, we contribute by studying immune responses in greater depth, helping to bridge the gap between controlled studies and real-world impact. During the meeting, scientists shared the latest developments. Key project milestones have already been reached, and the work is in full swing!

Next step: in June, the first results of the non-human primate trial will become available along with key samples to further investigate the immune mechanisms behind protection.

#CAPTIVATE #MalariaResearch #VaccineDevelopment #BPRC #EUfunded

bart faber Eva Iliopoulou Gemma Hartley Catherine Moreau Blandine Franke-Fayard Sander Wuyts, PhD 🧬 Cynthia Crul

Things to Do and Not to Do When Vaccinating Birds 🐓💉


✅ Things to Do When Vaccinating Birds
Use healthy birds only – Vaccinate only birds that are active and disease-free.Only vaccinate healthy birds; postpone vaccination if the flock is showing signs of illness.
Follow vaccination schedule – Give vaccines at the correct age and time.
Maintain cold chain (2–8°C) – Keep vaccines in a refrigerator or ice pack.Bring them out of the cooler only when ready to use.
Use clean water for vaccines – Especially for drinking-water vaccines.
Use sterile equipment – Clean syringes and droppers should be used.
Read manufacturer’s instructions – Follow dosage and method carefully.
Vaccinate early in the morning or evening – Avoid heat stress.
Withhold water for 1-4 hours before vaccination to ensure birds are thirsty.
Mix vaccine properly – Ensure even distribution in water or solution.
Consider adding skim milk powder (about 2g per liter) to stabilize the vaccine.
Ensure the vaccine is consumed within 1-2 hours.
Record vaccination details – Date, vaccine name, age of birds, batch number.
Walk through the house to encourage birds to move around and drink or if in Battery cage system, ensure the nipples are not blocked.
Observe birds after vaccination – Monitor for reactions or stress.

❌ Things Not to Do When Vaccinating Birds
Do not vaccinate sick birds – It may worsen their condition.
Do not use expired vaccines – They will not work effectively.
Do not expose vaccines to sunlight or heat – This destroys the vaccine.
Do not mix vaccines with dirty water – It reduces effectiveness.
Do not use antibiotics before or after vaccination – May affect vaccine response.
Do not overcrowd birds during vaccination – Causes stress.
Do not open vaccine long before use – Use immediately after opening.
Do not use chlorinated water – Chlorine kills live vaccines.
Do not skip booster doses – Immunity will be weak.
Do not vaccinate during extreme weather – Heat or cold affects immunity.

#GoodManagementPractices
#DiseasePrevention
#HealthyLivestock
#ImprovedProfitability
#BetterSuistainability
#PublicHealth

#MeaslesVaccine #LiveAttenuatedVaccine #VaccineInnovation #Immunization #VaccineDevelopment #PublicHealth #VaccineResearch #VaccineMarket #Biotech #Pharmaceuticals #VaccineManufacturing #VaccineDistribution #VaccineEfficacy #VaccineSafety #GlobalHealth #VaccineAwareness #VaccineTechnology #VaccineIndustry #HealthcareInnovation #VaccineCoverage #VaccineAdvancement #VaccineStrategy #VaccinePolicy #VaccineNews #VaccineTrends #HealthTech

🚀 [JOURNÉES SCIENTIFIQUES]

La « reverse vaccinology 3.0 » consiste à utiliser l’intelligence artificielle (#IA) pour prédire des structures antigéniques et d’interactions anticorps-antigène. Elle a notamment mené à l’identification d’une protéine utile à la neutralisation de certaines formes de variole, variole bovine ou variole du singe.

Explications par Dr Emanuele Andreano, Ph.D., head of serology and immunology à la Fondazione Biotecnopolo di Siena, à l’occasion des Journées scientifiques 2026 de l’ANRS Maladies infectieuses émergentes.

Pour suivre l'événement en direct : https://lnkd.in/eMQNpdPr

Pour en savoir plus : https://lnkd.in/ekD8FVqH

#science #santé #recherche #médecine #épidémies

https://lnkd.in/ecjcQx65

The most critical strategy for controlling the spread of infectious diseases is vaccination—making vaccine production processes pivotal to disease control and eventual eradication. Vaccination is an artificial process where inactivated, attenuated infectious pathogens, or their components, are delivered to the human body, using antigenic structures to activate the immune system. This process stimulates an effective response against specific pathogens to combat impending infections.

Since the mid-20th century, viral vaccines have been produced using chicken embryos, with dozens of approved traditional human vaccines manufactured via embryo-based processes. Today, however, cell culture-based vaccine production has become widespread: it enables simple infection and replication in controlled environments, with harvesting steps conducted in closed bioreactor systems to ensure sterility and further reduce biosafety risks through automation. This approach significantly boosts factory capacity, enabling the production of large quantities of vaccine doses.